Cancer cells often have upregulated DNA repair pathways, including NHEJ, to survive the high levels of DNA damage they incur. Inhibitors targeting components of the NHEJ pathway, such as DNA-PKcs inhibitors, are being investigated for their potential to sensitize cancer cells to chemotherapy and radiotherapy.
